Analysts See Daiichi Weathering Ranbaxy Merger Fallout

Daiichi Sankyo's beginnings as the parent of Ranbaxy Laboratories of India is costing the Japanese firm in the short run, but the deal still is expected to be beneficial in the long run, according to analysts. Since acquiring Ranbaxy, Daiichi has seen its shares under pressure because of problems with two of the Indian drug maker's factories that led to a temporary U.S. ban on its products. Analysts expect Daiichi to weather the fallout and become more stable with Ranbaxy as a subsidiary. (Click here for more - a subscription may be required